Drug Profile
Redaporfin - Luzitin
Alternative Names: LUZ-11Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Bluepharma; Universidade de Coimbra
- Developer Luzitin
- Class Antineoplastics; Macrocyclic compounds; Porphyrins
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Head and neck cancer
Most Recent Events
- 02 Apr 2024 Phase I/II development is ongoing in Portugal (EudraCT2013-003133-14) (NCT02070432)
- 28 Sep 2021 No development reported - Phase-II for Head and neck cancer (Late-stage disease) in Portugal (IV)
- 02 Jun 2017 Adverse events, efficacy and pharmacokinetics data from a phase II trial in Head and neck cancer presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)